CYTARABINE 5'-PHOSPHATE

Summary

Cytarabine 5’-Phosphate (CHEMBL596186) is a phase-3 clinical-stage small molecule; indicated across 1 condition including acute myeloid leukemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Chemistry: 323.2 Da · C9H14N3O8P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL596186
Name	CYTARABINE 5’-PHOSPHATE
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	65177
Molecular formula	C9H14N3O8P
Molecular weight	323.2
InChIKey	IERHLVCPSMICTF-CCXZUQQUSA-N

SMILES: C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O

IUPAC name: [(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate

Also known as: Ara-cytidine monophosphate, Aracmp, Aracytidine 5’-monophosphate, Aracytidine 5’-phosphate, Ara-5’-cmp, Cytarabine 5’-phosphate, Cytosine arabinoside 5’-phosphate, NSC-99445, CYTARABINE 5’-PHOSPHATE

Patent coverage: 30 distinct patent families (69 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).